Adventrx Pharmaceuticals (ANX) Income Statement

Click line-items for a historical chart and %

Licensing revenue
Net sales
Grant revenue
Total net revenue	45K
Cost of sales
Gross margin
Research and development	5.09M
Selling, general and administrative	2.13M
Transaction-related expenses
Depreciation and amortization	24K
In-process research and development
Impairment loss
Equity in loss of investee
Total operating expenses	7.25M
Loss from operations	-7.2M
Loss on fair value of warrants
Interest income	31K
Interest expense	-948K
Other income (expense)	-34K
Loss before cumulative effect of change in accounting principle
Cumulative effect of change in accounting principle
Net loss	-8.15M
Preferred stock dividends
Deemed dividends on preferred stock
Net loss applicable to common stock
Net loss per common share - basic and diluted	-0.04
Weighted average shares - basic and diluted

Entities mentioned with ANX

View All Entities